Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 5/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 6/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.38 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.37 |
| ▸ | RBP4 | P02753 | 1/20 | 0.37 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.36 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.35 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.35 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.35 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1152551 | 0.95 | L3MBTL1 (0.41) | ALDH1A1HPGDHTTGAAMEN1 | |
| SCHEMBL1153692 | 0.95 | HTT (0.39) | ALDH1A1HPGDHTTGAAMEN1 | |
| SCHEMBL1153308 | 0.94 | L3MBTL1 (0.40) | ALDH1A1HPGDHTTGAAMEN1 | |
| SCHEMBL4332813 | 0.84 | ALDH1A1 (0.46) | ALDH1A1HPGDHTTGAAMEN1 | |
| SCHEMBL1153785 | 0.84 | GAA (0.41) | ALDH1A1HPGDHTTGAAMEN1 | |
| SCHEMBL1153753 | 0.82 | GAA (0.40) | ALDH1A1HPGDHTTGAAMEN1 | |
| SCHEMBL4339894 | 0.82 | ALDH1A1 (0.44) | ALDH1A1HPGDHTTGAAMEN1 | |
| SCHEMBL808735 | 0.82 | MEN1 (0.44) | ALDH1A1HTTGAAMEN1KMT2A | |
| SCHEMBL1152091 | 0.81 | GAA (0.40) | ALDH1A1HPGDHTTGAAMEN1 | |
| SCHEMBL4337750 | 0.81 | ALDH1A1 (0.45) | ALDH1A1HPGDHTTGAAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7943799-B2 | Method for producing optically active cycloalkylidenebisoxazoline compound and intermediate thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2011-05-17 | — | — | US | disclosed |
| US-20110046415-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE CYCLOALKYLIDENEBISOXAZOLINE COMPOUND AND INTERMEDIATE THEREOF | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2011-02-24 | — | — | US | disclosed |
| US-7842839-B2 | Method for producing optically active cycloalkylidenebisoxazoline compound and intermediate thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2010-11-30 | — | — | US | disclosed |
| US-20070112201-A1 | Method for producing optically active cycloalkylidenebisoxazoline compound and intermediate thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2007-05-17 | — | — | US | disclosed |
| EP-1698617-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE CYCLOALKYLIDENE BISOXAZOLINE COMPOUND AND INTERMEDIATE THEREOF | Sumitomo Chemical Company, Limited (JP) | 2006-09-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070112201-A1 | Method for producing optically active cycloalkylidenebisoxazoline compound and intermediate thereof | CYP3A7, GRK7, CYP2A7 | ALDH1A1 610/4885HPGD 4153/4885HTT 3621/4885 |
| US-20110046415-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE CYCLOALKYLIDENEBISOXAZOLINE COMPOUND AND INTERMEDIATE THEREOF | CYP3A7, GRK7, CYP2A7 | ALDH1A1 610/4885HPGD 4153/4885HTT 3621/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.